EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Impact of SGLT1 Inhibition on Frailty and Sarcopenia: A Mediation Mendelian Randomization Study

Bang-Bang Huang, Yu-Jie Zhang, Guang-Feng Ruan, Xing Yu, Qin Liu, Mei-Jin Zhang, Ming-Zhong Yu, Ai Chen, Ye-Bei Liang, Liang-Di Xie, Li Luo

Journal of Cachexia, Sarcopenia and Muscle · 2024

DOI: 10.1002/jcsm.13614 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2024. Verfasst von Bang-Bang Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, First Affiliated Hospital of Fujian Medical University, Institute of Neuroscience, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Sarcopenia, Mendelian Randomization Analysis, Frailty, Sodium-Glucose Transporter 1. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Joint Funds for the Innovation of Science and Technology, Fujian Province, National Natural Science Foundation of China, Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although pharmacological effects of SGLT2 inhibitors on the development of frailty and sarcopenia were known, the role of SGLT1 remained less clear. The present study investigated the possible effect of SGLT1 inhibition on these conditions and explored potential mediators.

Methods

A two‐sample Mendelian randomization (MR) analysis was performed to assess the effect of SGLT1 inhibition on frailty index (FI) and low grip strength in individuals aged 60 years and older using both the FNIH and EWGSOP criteria. Subsequently, a two‐step MR analysis was conducted to investigate the mediating role of insulin resistance phenotype and identify potential mediators of the effect of SGLT1 inhibition on the FI and low grip strength from 1558 plasma proteins and 1352 metabolites.

Results

Genetically predicted SGLT1 inhibition was associated with decreased FI ( β : −0.290 [95% CI: −0.399, −0.181]) and reduced risk of low grip strength in individuals aged 60 years and older under both FNIH ( β : −0.796 [95% CI: −1.216, −0.376]) and EWGSOP criteria ( β : −0.287 [95% CI: −0.532, −0.041]). The two‐step MR analysis demonstrated the role of insulin resistance phenotype in mediating SGTL1 inhibition on alleviating frailty (mediation proportion = 19.56% [95% CI: 8.42%, 30.70%]). After screening, 24 proteins and 16 metabolites were identified as mediators of the impact of SGLT1 inhibition on FI. Additionally, 13 proteins and 16 metabolites were found to mediate the effect of SGLT1 inhibition on low grip strength according to FNIH criteria while 22 proteins and 6 metabolites were shown to mediate the impact of SGLT1 inhibition on low grip strength under EWGSOP criteria.

Conclusions

SGLT1 inhibition potentially mitigated frailty and sarcopenia through several biological mediators, shedding new light for therapeutic intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcopeniaMendelian Randomization AnalysisFrailtySodium-Glucose Transporter 1HumansAgedMaleFemaleMiddle AgedHand StrengthSodium-Glucose Transporter 2 Inhibitors

Stichwörter der Autor:innen

Mendelian randomizationSGLT1 inhibitionfrailtysarcopenia

Substanzen

Sodium-Glucose Transporter 1SLC5A1 protein, humanSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Geriatrics, First Affiliated Hospital of Fujian Medical University, Institute of Neuroscience, Fujian Medical University, Fuzhou, China.
  • Fujian Hypertension Research Institute, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Department of Geriatrics, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Clinical Research Center for Geriatric Hypertension Disease of Fujian Province, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Branch of National Clinical Research Center for Aging and Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Department of Geriatrics, First Affiliated Hospital of Fujian Medical University, Fujian Key Laboratory of Molecular Neurology and Institute of Neuroscience, Fujian Medical University, Fuzhou, China.

Förderung

  • Joint Funds for the Innovation of Science and Technology, Fujian Province
  • National Natural Science Foundation of China
  • Natural Science Foundation of China

Zitieren

APA

Huang, B. B., Zhang, Y. J., Ruan, G. F., Yu, X., Liu, Q., Zhang, M. J., Yu, M. Z., Chen, A., Liang, Y. B., Xie, L. D., & Luo, L. (2024). The Impact of SGLT1 Inhibition on Frailty and Sarcopenia: A Mediation Mendelian Randomization Study. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13614

Vancouver

Huang BB, Zhang YJ, Ruan GF, Yu X, Liu Q, Zhang MJ, et al. The Impact of SGLT1 Inhibition on Frailty and Sarcopenia: A Mediation Mendelian Randomization Study. Journal of Cachexia, Sarcopenia and Muscle. 2024. doi:10.1002/jcsm.13614

BibTeX
@article{Huang2024,
  author = {Huang, Bang-Bang and Zhang, Yu-Jie and Ruan, Guang-Feng and Yu, Xing and Liu, Qin and Zhang, Mei-Jin and Yu, Ming-Zhong and Chen, Ai and Liang, Ye-Bei and Xie, Liang-Di and Luo, Li},
  title = {The Impact of SGLT1 Inhibition on Frailty and Sarcopenia: A Mediation Mendelian Randomization Study},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2024},
  doi = {10.1002/jcsm.13614}
}
Kostenlos starten →